Publications by authors named "Benjamin Henley"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

335,919

Total Likes

10,316

Extended Reach

721,340

Social Features

188
A
Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression.
Ricardo Rivera-Soto, Benjamin Henley, Marian A Pulgar, Stacey L Lehman, Himanshu Gupta

NPJ Precis Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highest ocean heat in four centuries places Great Barrier Reef in danger.
Benjamin J Henley, Helen V McGregor, Andrew D King, Ove Hoegh-Guldberg, Ariella K Arzey

Nature· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Technological drought: a new category of water scarcity.
Md Anarul Haque Mondol, Xuan Zhu, David Dunkerley, Benjamin J Henley

J Environ Manage· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decadal climate variability in the tropical Pacific: Characteristics, causes, predictability, and prospects.
Scott Power, Matthieu Lengaigne, Antonietta Capotondi, Myriam Khodri, Jérôme Vialard, Benjamin J Henley

Science· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kainate and AMPA receptors in epilepsy: Cell biology, signalling pathways and possible crosstalk.
Jeremy M Henley, Jithin D Nair, Richard Seager, Busra P Yucel, Gavin Woodhall, Benjamin S Henley

Neuropharmacology· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis.
Smruthi Vijayaraghavan, Lorraine Lipfert, Kristen Chevalier, Barbara S Bushey, Benjamin Henley

Mol Cancer Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in excitatory and inhibitory receptor expression and network activity during induction and establishment of epilepsy in the rat Reduced Intensity Status Epilepticus (RISE) model.
Hope I Needs, Benjamin S Henley, Damiana Cavallo, Sonam Gurung, Tamara Modebadze, Jeremy M Henley

Neuropharmacology· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy.
Urvashi V Roongta, Jonathan G Pabalan, Xinyu Wang, Rolf-Peter Ryseck, Joseph Fargnoli, Benjamin J Henley

Mol Cancer Res· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.
Tai W Wong, Francis Y Lee, Stuart Emanuel, Craig Fairchild, Joseph Fargnoli, Benjamin Henley

Clin Cancer Res· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
David K Williams, Xiao-Tao Chen, Christine Tarby, Robert Kaltenbach, Zhen-Wei Cai, Benjamin J Henley

Bioorg Med Chem Lett· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.
Rajeev S Bhide, Louis J Lombardo, John T Hunt, Zhen-Wei Cai, Joel C Barrish, Benjamin J Henley

Mol Cancer Ther· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.
Gretchen M Schroeder, Yongmi An, Zhen-Wei Cai, Xiao-Tao Chen, Cheryl Clark, Benjamin Henley

J Med Chem· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities.
Kyoung Soon Kim, Liping Zhang, Robert Schmidt, Zhen-Wei Cai, Donna Wei, Benjamin Henley

J Med Chem· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.
Réjean Ruel, Carl Thibeault, Alexandre L'Heureux, Alain Martel, Zhen-Wei Cai, Benjamin Henley

Bioorg Med Chem Lett· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.
Zhen-Wei Cai, Donna Wei, Robert M Borzilleri, Ligang Qian, Amrita Kamath, Benjamin J Henley

Bioorg Med Chem Lett· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis